rhIFN-aA Liquid. In PBS containing 0.1% BSA. AVOID FREEZE/THAW CYCLES. Recombinant, human aA-interferon expressed in E. coli. Antiviral, anti-neoplastic agent. aA-Interferon exhibits therapeutic potential with chronic viral hepatitis, polycythemia vera, and various malignancies. It enhances natural killer cell activity, suppresses bone marrow function, and induces apoptotic cell death in non-melanoma skin cancer. NOTE: 1MU = 1,000,000 units. Activity: ≥5 x 106 units/ml. Specific activity: ≥2.8 x 108 units/mg protein. One unit of interferon per ml of medium will cause a 50% inhibition of VSV-induced cytopathic effect on bovine MDBK cells. Units are determined with respect to the NIH international reference standard for human aA-IFN. Dilute in aqueous buffer containing at least 0.1% BSA or HSA. Purity: ≥95% by SDS-PAGE. Note: 1 MU = 1,000,000 units. Merck Index: 14, 4990
Ref.: Fujishima, H., et al. 1998. Int. J. Cancer 76, 423. Haria, M., and Benfield, P. 1995. Drugs 50, 873. Familletti, P.C., et al. 1981. Methods Enzymol. 78, 387. |
